Evidence map›Paper›PMID 35747921›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Research Progress of Pharmacological Therapy and Nutritional Support for Cachexia 
in Lung Cancer Patients].

Jiemin Wang, Weihui Jia, Danyang Li, Yanmei Song, Ningxin Sun, Ke Yang, Hongli Li, Chonggao Yin

Open access · greenAbstract readReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jiemin WangColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Weihui JiaColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Danyang LiColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Yanmei SongColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Ningxin SunColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Ke YangColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Hongli LiMedical Research Center, Weifang Medical University, Weifang 261053, China.
Chonggao YinColloge of Nursing, Weifang Medical University, Weifang 261053, China.
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cachexia is a common complication in patients with lung cancer. It aggravates the toxic and side effects of chemotherapy, hinders the treatment plan, weakens the responsiveness of chemotherapy, reduces the quality of life, increases complications and mortality, and seriously endangers the physical and mental health of patients with lung cancer. The causes and pathogenesis of tumor cachexia are extremely complex, which makes its treatment difficult and complex. Controlling cachexia in lung cancer patients requires many means such as anti-tumor therapy, inhibition of inflammatory response, nutritional support, physical exercise, and relief of symptoms to exert the synergistic effect of multimodal therapy against multiple mechanisms of tumor cachexia. To date, there has been a consensus within the discipline that no single therapy can control the development of cachexia. Some therapies have made some progress, but they need to be implemented in combination with multimodal therapy after fully assessing the individual characteristics of lung cancer patients. This article reviews the application of drug therapy and nutritional support in lung cancer patients, and looks forward to the research direction of cachexia control in lung cancer patients.
.

Indexed as

Lung NeoplasmsNeoplasmsCachexiaCombined Modality TherapyHumansNutritional SupportQuality of LifeCachexiaCombined modality therapyDrug therapyLung neoplasmsNutritional support

Identifiers

PMID35747921
PMCPMC9244501
OpenAlexW4283464968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.